Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
PMID: 32163527
2020
Drugs of today (Barcelona, Spain
Abstract: It has a novel resistance pathway so that it retains in vitro activity against clinically relevant NNRTI viral mutations K103N, Y181C and G190A.
Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
Introduction: Across those clinical isolates (no subtype information was provided), DOR displayed a good antiviral activity with fold changes in EC50<9 against most single mutant viruses, including A98G, E138A/G/K/Q, G190A, K101E/P, K103N/S, L100I, P236L, V106M, V108I, V197D, V90I, Y181C/V, and Y188H/C.
Introduction: Importantly, preliminary clinical data obtained from a small number of participants (n=9) indicated that DOR could be used efficaciously to suppress viral replication for 96 weeks in
Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China.
Discussion: K103N/S (41.32%) was the most frequently observed resistance mutation in NNRTIs, followed by Y181C(27.83%) and G190A(26.21%), This is a consequence of the frequent use of NNRTI-based (EFV/NVP) first-line therapy for more than a decade in China, and these results are similar to the data from low- and middle-income countries.
Discussion: G190A caused high-level resistance to NVP and intermediate resistance to EFV and could result in attenuation of the resistance that occurs with K103N alone, and G190A had a higher frequency (83.47%) of drug resistance in the HIV-1 CRF 01AE subtype in this study.
Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
Introduction: Moreover, an OLA-Simple kit that detects the NRTI mutation M184V and NNRTI mutations K103N,
Result: False-positive occurred at M184V (n = 2/59) and G190A (n = 3/59); all these false-positives by OLA-Simple were 100% wild-type by MiSeq.
Result: OLA-Simple genotyping was indeterminate (IND) for 2.7% (8/295) of all codons tested (Table 1), with 8.5% (5/59) at K65R, 3.4% (2/59) at Y181C, and 1.7% (1/59) at G190A.
Result: Of the four false-negative results, three were K103N/S (at 10.5, 11.9, and 22.4% mutant frequency) and one at G190A (at 20.59% mutant frequency).
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
PMID: 32259255
2020
The Journal of antimicrobial chemotherapy
Abstract: Some RT variants became dominant at VF (K101E, 86.3%; Y181C, 100.0%; G190A, 100.0%) and others emerged in integrase (Y143C, 2.4%; Q148R, 6.2%; N155H, 18.8%).
Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
Result: G190G/A occurred in six (6%) patients receiving AZT plus 3TC, and in three (3%) patients receiving ABC plus 3TC.
Table: G190A/S
Discussion: The group receiving AZT plus 3TC or ABC plus 3TC showed the highest rates of NNRTI mutations such as P225H, V106M, E138A/G/K/Q, G190A/S, and Y188L occurred most frequently in patients receiving AZT plus 3TC or ABC plus 3TC.
HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.
Result: K103N (37.55%, 92/245) was the most frequent mutation, followed by Discussion: K101 E/H/P, Y181 C/V, and G190 A/E/K/Q/S/V are broad spectrum general mutations resistant to all NNRTIs.
Discussion: NRTI-associated DRMs M184I/V and K65R and NNRTI-associated DRMs with extensively drug resistance K101E/H/P, V179I/D/E/T, Y181C/V, and G190A/E/K/Q/S/V were detected in CRF55_01B.
The characteristics of pretreatment HIV-1 drug resistance in western Yunnan, China.
Abstract: Among the DRMs detected, some independently conferred resistance, such as K65R (1.6%, 5/322), Y188C/F/L (0.9%, 3/322), K103N (0.6%, 2/322) and G190A (0.3%, 1/322), which conferred high-level resistance.
Result: Among the key DRMs for NNRTIs, Y188C/F/L (0.9%, 3/322), K103N (0.6%, 2/322) and G190A (0.3%, 1/322) conferred high-level resistance, K101E (0.9%, 3/322) and P225H (0.9%, 3/322) conferred intermediate resistance and H221Y (0.9%, 3/322) conferred low-level resistance.
Table: G190A
Discussion: Among the PMID: 32434561
2020
AIDS research and therapy
Table: G190A
Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries.
PMID: 32522826
2020
Journal of clinical microbiology
Abstract: In a cross-sectional study (June 2018 to September 2019), we evaluated the diagnostic accuracy of a simple and rapid HIVDR assay (the pan-degenerate amplification and adaptation [PANDAA] assay targeting the mutations K65R, K103NS, M184VI, Y181C, and G190A) compared to Sanger sequencing and next-generation sequencing (NGS).
Abstract: PANDAA showed strong agreement with Sanger sequencing for K65R, K103NS, M184VI, and G190A (kappa > 0.85) and substantial agreement for Y181C (kappa = 0.720).
HIV mutation literature information.
PMID: 
2020
Drugs of today (Barcelona, Spain
Browser Board
Co-occurred Entities
Filtrator
ViMRT